



**SWIM**  
ACROSS AMERICA  
★ MAKING WAVES TO FIGHT CANCER ★

**NASSAU—SUFFOLK 2018**  
**SOUND TO COVE OPEN WATER SWIM**  
**FAMILY FUN SWIM ★ POOL SWIMS**  
**AUGUST 4, 2018**

★ MAKING WAVES TO FIGHT CANCER ★



# SWIM ACROSS AMERICA

is proud to thank

## GARY LEHMAN

for your boundless spirit and dedication to Swim Across America!

From swimming, to hiking, to your exquisite photography, you have lifted our mission to NEW HEIGHTS, and helped capture the enthusiasm of all those that participate in our fight to DEFEAT cancer!

★ MAKING WAVES TO FIGHT CANCER ★



# DID YOU KNOW ?

2018 will mark the 31st year of Swim Across America. During that time, we've grown from a single event in Nantucket, MA, to the 18 open water benefit swims across the country and 100 annual pool swims.



## \$75 MILLION

Since 1987, SAA has raised over \$75 million through 18 experiential open water swimming fundraising events and over 100 pool swim fundraisers




**18 Open Water Swims**  
across the country



Every **15 minutes, 50 Americans**  
are diagnosed with cancer



For every **dollar** we grant, our beneficiaries have been able to secure **three** or more dollars in new funding they might otherwise have not received



**100%** of each SAA grant must be applied to the approved clinical trial or research project

## 2018 SOUND TO COVE OLYMPIANS



**Michael Phelps and 120+ Olympians** support SAA



### CRAIG BEARDSLEY

Craig Beardsley was heavily favored to win the 200m butterfly as a member of the 1980 Olympic Team, only to be forced from competition when politics intervened, and the US boycotted Moscow's Summer Games. Between 1980 and 1983, Craig held both the World and the American Records in the 200m butterfly, and he won Gold at the Pan American Games in both 1979 and 1983. A nine-time US National Champion, Craig captured another Gold in the same event at the NCAA Championships while an All-American at the University of Florida.



### STEVE LUNDQUIST

In 1984 at the LA Olympic Games, Steve emerged as the best American breastroker in the history of international swimming. There he earned two Gold Medals while setting two World Records in the 100m breast and 100m medley relay. Throughout his swimming career, Steve broke World and American Records on 15 occasions. An inductee into the International Swimming Hall of Fame in 1990, he was honored again six years later by being the flagbearer for the Olympic Games in Atlanta.

# NASSAU—SUFFOLK

★ MAKING WAVES TO FIGHT CANCER ★

## EXECUTIVE COMMITTEE

Gerry Oakes  
Kevin Shine  
Pamela Danbusky  
Joe & Vickie Stanco  
Alexa Stanco  
Kenneth Aneser  
Darcy Belyea  
Daniel Cavallo, III  
John Coyle  
Mike Ford  
Jessica Foschi Gallo  
Joe Kasper  
Ellen Leondis  
Tony Leondis  
Eileen & James Liddy  
Carol Maroney  
Maureen McAdam  
Don Regan  
Rob Ripp  
Paul Van Valkenburg



## 2018 POOL SWIMS

Centerport / Huntington YC  
Garden City Pool  
Harborfields / Smithtown HS Pool  
LIAC / Long Island Swim School  
Long Island Swimming Aquatic Center  
Lynbrook Pool  
Mid Island Y JCC  
North Hempstead CC Pool  
Plandome GC Pool  
Rockville Links CC  
SAA Nassau / Suffolk Invitational Swim  
Silver Point Beach Club  
Team Suffolk Pool

*Thank  
you!*

A very special thanks to our swimmers, boaters and kayakers, volunteers, sponsors, event committee and Olympic Swimmers, and to Mayor Tim Tenke and the City of Glen Cove, Nassau County Executive Laura Curran, Glen Cove Director of Parks and Recreation Darcy Belyea and her team, Glen Cove Yacht Club, Glen Cove Harbor Patrol, Glen Cove Police Department, Glen Cove Fire Department, Glen Cove EMS, Nassau County Marine Bureau, Rye Police Department; and to Mike at Glen Cove Beer Distributors for the ice, Starbucks of Glen Cove, Greenvale Bagels, Bagel Café of Glen Cove, Arizona Iced Tea and Canteen for their generous donations of food and beverages—we couldn't do it without you!

## NATIONAL PARTNERS



## **2018 TRIBUTE TEAMS**

**Cold Spring Harbor Laboratory**

**Dad's Aquatic Warriors**

**Glen Cove C.A.R.E.S.**

**Heal the World**

**Our Answer to Cancer**

**Team CommScope**

**Team Dream**

**Team Feinstein**

**TEAM HOPE**

**Team Merck—Sound to Cove**

**Team NCPD**

**TEAM STACEY**

**TEAM UBS**

**Team West Neck Pod**

**TOAST**

Tribute Teams are central to what Swim Across America is all about - friends and family joining together to fight cancer.

Our teams are core to the camaraderie and success of our SAA events. Some teams swim in honor of friends and loved ones currently battling cancer, others swim in memory of those who have lost their battle.



# NASSAU-SUFFOLK

★ MAKING WAVES TO FIGHT CANCER ★




**\$8.9 M+**  
raised by SAA  
Nassau-Suffolk  
since 2001

81%+ of donations  
go to our Beneficiaries



**Sound to Cove Open  
Water Swim and  
10+ Pool/Club Swims**



There are **nine named Swim Across America research labs** demonstrating the commitment and partnership of the beneficiary and Swim Across America, including:  
**Memorial Sloan Kettering Cancer Center**  
and **Johns Hopkins Medicine**





# Cold Spring Harbor Laboratory

Bruce Stillman, Ph.D., F.R.S.  
President

William J. Matheson Professor  
of Cancer Biology

July 17, 2018

Swim Across America  
Nassau Suffolk Journal  
c/o 11600 N. Community House Road  
Charlotte, NC 28277

## **Cold Spring Harbor Laboratory 2018 Testimonial**

Dear Friends,

Since 2008, SAA has committed \$720,000 to Cold Spring Harbor Laboratory's (CSHL) cancer research toward innovative, collaborative projects in cancer recurrence, immunotherapy and cutting-edge translational programs. We are profoundly grateful to SAA for recognizing the importance of supporting early-stage discovery programs - risky, innovative science not yet eligible for government funding.

SAA support helps members of CSHL's Cancer Center explore the fundamental biology of human cancer using focused, multi-disciplinary approaches to break new ground in basic tumor biology and develop innovative, advanced technologies.

Three Scientific Programs provide focus in Gene Regulation & Cell Proliferation; Signal Transduction; and Cancer Genetics. In addition, nine Shared Resources offer essential access to technologies, services, and expertise that enhance productivity. With a strong collaborative environment and open communication, the CSHL Cancer Center is able to make breakthroughs in cancer biology that are translating into real progress in cancer diagnostics and treatment.

Today, this work is leading toward the development of effective new diagnoses and therapeutics for several cancer types.

With gratitude,

Bruce Stillman



## Memorial Sloan Kettering Cancer Center

### **Swim Across America Laboratory Memorial Sloan Kettering Cancer Center June 19, 2018**

To our friends of Swim Across America:

The physicians and scientists of the Swim Across America Laboratory at Memorial Sloan Kettering Cancer Center (MSK) are very grateful for your generous support. Every one of our team members benefit from your kindness, and is deeply appreciative to all the swimmers and volunteers taking part in Swim Across America's events over the past year.

Our Swim Across America Laboratory continues to make progress translating the results of our basic research program into new treatments for cancer patients. In addition, we have been able to build a new network of collaborations in diverse fields to complement our research, and attract more funding to the rapidly expanding field of immunotherapy. Without your support, none of this would have been possible.

We continue to focus on improving and developing new approaches to cancer treatment, especially those that target the immune system. The immune system is programmed to recognize foreign organisms and has difficulty destroying cancer cells because the disease arises from one's own tissues. The investigators in the Swim Across America Laboratory are working on novel ways to overcome resistance and stimulate the immune system to destroy cancer.

While melanoma is our model system, we strive to adapt these strategies and treatments to many different cancer types—so far, for patients with non-small cell lung cancer, Hodgkin lymphoma, renal cell carcinoma, and metastatic bladder cancer. One of our top questions is why this approach is so active in some cancers but ineffective in others. Early observations suggest detectable differences in blood after treatment, including changes in certain T cells that express high levels of the marker PD-1 (Huang et al, Nature 2017). More recently, we discovered a new immune cell group that may be a marker of treatment response. (We know that tumors protect themselves by attracting immunosuppressive cells, which surround the cancer and dampen the anti-tumor immune response. One well-studied example is a marker called Foxp3.) The cells newly defined by our team do not express Foxp3 but do contain high levels of PD-1.

Interestingly, they appear to be affected in opposite ways by the two main types of FDA-approved checkpoint drugs: the anti-PD-1 drugs suppress the non-Foxp3 expressing cells, which are actually expanded by anti-CTLA-4 drugs. This could explain why the anti-CTLA-4 therapy works much better when combined with an anti-PD-1 drug. Going forward, the new immune cell type—measurable with a blood test—could show the treatment team how well the two checkpoint inhibitors are doing at hitting their targets. Depending on the results, physicians can adjust drug dosage as needed. (Zappasodi et al, Cancer Cell, 2018).

Presently, we are collecting blood from patients treated with ipilimumab, nivolumab, and other immunotherapies to evaluate the influence of the biomarkers identified so far. We have also started analyzing the immune T cell diversity in the blood of these patients by conducting next-generation sequencing of the T cell receptors; this will help us determine how this diversity affects treatment response.

Previous research showed that a tumor's genetic landscape determines a person's clinical response to ipilimumab. Now, the Swim Across America Laboratory is assessing the genetic footprint in tumors from patients untreated or treated with nivolumab and/or the combination of ipilimumab plus nivolumab. Following another approach (Snyder A, et al, New England Journal of Medicine, 2014), we analyzed patients with pancreatic ductal adenocarcinoma, an aggressive malignancy where less than seven percent of patients live past five years. Using whole-exome sequencing and tools to predict neoantigens (which cancer cells accumulate as a result of mutations when they divide), we found that tumors containing the highest numbers of neoantigens and CD8+ T cells were associated with the longest survival. Our results (Balachandran et al, Nature 2017) identify neoantigens with unique qualities that could serve as T-cell targets against pancreatic cancer. Following this logic, we were able to predict survival for individuals treated with anti-CTLA-4 for melanoma, and those treated with anti-PD-1 for lung cancer. And notably, neoantigens deemed "low fitness" could be used as targets for novel immunotherapies and vaccine strategies. This new "fitness" model can reveal similarities between the evolution of tumors and rapidly changing pathogens in checkpoint blockade as described above in untreated pancreatic cancer patients (Luksza et al, Nature 2017).

Another aspect of our research focuses on overcoming resistance to checkpoint blockade by manipulating the various mechanisms within the tumor microenvironment. The enzymatic breakdown of the amino acid tryptophan into metabolized pieces known as kynurenines (Kyn) has been described as a major source of immune suppression in different tumor types. As presented at the American Association of Cancer Research's 2018 meeting, our findings demonstrate that targeting the Kyn pathway by halting the AhR gene is a promising approach in cancer patients resistant to immune-checkpoint blockade.

Oncolytic viruses are another type of cancer therapy that can overcome resistance to anti-CTLA-4 and anti-PD1/PD-L1 regimens. These viruses are unique because in addition to their cancer cell-killing activity when injected into tumors, they induce strong inflammation and increased immune cell infiltration. We have identified a range of immune targets using a variety of different models treated with Newcastle disease virus (NDV). Early research showed that systemic therapeutic PD-1/PD-L1 in combination with NDV slowed the growth of both treated and distant tumors. These findings (Zamarin et al, Journal of Clinical Invest, 2018) have implications for the timing of PD-1/PD-L1 blockade in conjunction with virus therapy.

As you have read, MSK's Swim Across America Laboratory has experienced another highly productive year yielding many exciting results. Every step, every breakthrough represents incremental progress—and adds to an ever-growing arsenal of options for patients everywhere fighting cancer. We are tremendously grateful for your continued support and confidence in our team's ability to bring forward new and better approaches.

Warmest regards,




Jedd D. Wolchok, MD, PhD

**Jedd Wolchok, MD, PhD**  
Lloyd J. Old/Virginia and Daniel K. Ludwig Chair in Clinical Investigation  
Chief, Melanoma & Immunotherapeutic Service  
Director, Swim Across America Lab  
Director, Parker Institute for Cancer Immunotherapy  
Associate Director, Ludwig Center for Cancer Immunotherapy and  
Member, Ludwig Cancer Research  
Professor of Medicine, Weill Medical College of Cornell University  
wolchokj@mskcc.org  
1275 York Avenue, New York, NY 10065  
T 646-888-2315  
NCI-designated Comprehensive Cancer Center

July 16, 2018


Dear Swim Across America Friends:

Thank you for all the support you have provided for our laboratory over the past twelve years. We are extremely grateful for the contributions made by all of the participants and their supporters in the Sound to the Cove Swim and the other Swim Across America events. For the past nine years the support for our efforts has been provided in the form of a Research Fellowship named in honor of Stacey Leondis, who continues to remain an inspiration to all of us.



I am excited to write a letter this year which includes a thank you to the group visiting the MD Anderson Cancer Center in Houston, TX (April 19 – 20, 2018). I have always been impressed with the level of attention the Foundation and Chapter pays to details including the beneficiary committee's careful attention to how the hard-raised money is utilized. We were happy to present our work on a Webex and delighted to hear an in person visit was occurring. It was our pleasure to provide actual "hands-on demos" with Pamela and Ellen, during our lab visit which included running a Western blot, preparing and running an agarose gel, and then using the e-gel imager to check the DNA bands, along with other experiments. In the laboratory, Yifei, who is the Swim Across America Stacey Leondis Research Fellow, gave a presentation of his cytof project which is designed to identify surface proteins which can be targeted as a novel approach to treat osteosarcoma.

We were honored and extremely proud to give a quick tour of our Main Building facilities – including our Pediatric Oncology floor and outpatient clinic – as well as our South Campus facilities at the MD Anderson Cancer Center – and show you the strides that we are making at MD Anderson Children's Cancer Hospital. What a time we had and with it a tremendous opportunity for us to show what we do! Although I wanted to thank the group for the visit even more importantly the support that you provide allows us to continue our critical work to develop new treatments for osteosarcoma. Osteosarcoma is the most common primary bone cancer in teens and young adults and improving the outcome of this dreaded disease continues to be our single-minded focus. As an update on the numerous clinical trials that are ongoing driven by the work you have supported, whether that is the ganitumab (IGF-1R Ab trial), the dinituximab study (GD2 Ab), or the glembatumumab study (GPNMB antibody drug conjugate study) – they all continue to be ongoing with hopes they will represent a clinical advance. Just as an update on the study that is ongoing the longest



- the AEWS1221 study now has 252 patients on study out of a planned 300 patients. We are immensely excited about the new research methods that have become available to us at MD Anderson. Whether it be genomic profiling of a series of osteosarcomas from patients with recurrences or experiments profiling proteins on the surface of osteosarcoma, we get ever closer to realizing new effective treatments which is a critical need. Because of your support, hope remains alive, as we gain many new promising targeted therapies, to discuss in future years.

I look forward to once again being at the Swim Across America Sound to the Cove Swim in August in Glen Cove.

Like many others, each year we try to gather more swimmers and this year my daughter, Sarah, along with our niece Rachel, will join my wife, Anne and son, Joshua in swimming. We are only a small part of the tremendous number of swimmers, volunteers and supporters but we are happy to be part of this year's event as well.

Swim Across America is a wonderful organization and it was my pleasure to foster their interaction with MD Anderson now culminating with an event – Saturday, May 4, 2019 at Alexander Deussen Park in Lake Houston! Key to that event is Dr. John de Groot of MD Anderson, who leads the Department of Neuro- oncology and who is himself a Master Swimmer.


Please know that I treasure our partnership and our friendship - and am very grateful for you taking the time to visit Houston and for your support.

See you soon!

Sincerely,

A handwritten signature in black ink, appearing to read "Richard Gorlick".

Richard Gorlick, MD  
Division Head and Department Chair, Pediatrics  
Professor of Pediatrics  
Robert A. Mosbacher Chair of Pediatrics  
University of Texas MD Anderson Cancer  
Center Children's Cancer Hospital





July 2018

Dear Swim Across America Friends,

Our laboratory is truly honored and very grateful to be a beneficiary of Swim Across America. Your support is enabling us to identify new therapeutic approaches to treat medulloblastoma and glioma, the most common malignant brain tumors in children.

Significant progress has been made in the treatment of medulloblastoma patients over the past several decades. Unfortunately however, current therapies, in particular radiotherapy, have severe long-term side-effects in children, including marked neurocognitive difficulties. Therefore, there is a great need for new therapeutic strategies. Radio-sensitization, the combination of radiotherapy with rationally designed drugs, can achieve therapeutic benefit with lower doses of radiation, thereby diminishing the side-effects of radiotherapy and enhancing the quality of life of the patient. Work performed in our laboratory over the past several years resulted in the design and characterization of a powerful radio-sensitizer, M443, a drug that is still in development.

Another approach to radio-sensitize tumors is to target tumor-associated macrophages (TAMs). TAMs are attracted by tumors and in turn secrete factors that promote tumor cell survival after radiation treatment. In an initial search for drugs that deactivate TAMs, we identified the anti-inflammatory drug semapimod as a TAM inhibitor and found that it strongly sensitized glioma tumors to radiation therapy. The blood-brain barrier (BBB) constitutes a major obstacle for the delivery of drugs to brain tumors, and the BBB permeability of semapimod, like that of most drugs, is very low. As the rational design of BBB-permeable drugs remains extremely difficult, we are now testing TAM inhibitors that have demonstrated BBB permeability. Mounting evidence indicates that the damage caused by radiation therapy on the normal brain involves an inflammatory response. Thus, blocking radiation-induced inflammation also should be helpful in diminishing the side-effects of radiotherapy. We therefore are focusing our attention on several TAM inhibitors that have demonstrated anti-inflammatory activity and BBB permeability, with the goal of identifying drugs that can radio-sensitize brain tumors, while protecting the normal brain.

A major cause of treatment failure and disease recurrence in brain tumors and other cancers is a high degree of intra-tumor heterogeneity, illustrated by the observation that single cells from the same tumor often have different combinations of mutations that promote tumor cell survival and therapeutic resistance. We have identified a microRNA (miR-34a) that inhibits the expres-

sion of multiple survival genes and showed that it strongly sensitizes cells derived from different subtypes of glioblastoma tumors, a highly aggressive form of glioma, to both radio- and chemo-therapy. We recently succeeded in delivering this microRNA to glioblastoma tumors using a nanoparticle. We showed that these nanoparticles are highly effective in sensitizing these tumors to temozolomide, the standard chemotherapy that is used to treat patients with glioblastoma and anticipate to see similar sensitization to radiotherapy.

We are very encouraged by our recent findings and with your support, we look forward to further translate these results into clinical benefit for pediatric brain tumor patients.

Sincerely,



Marc Symons, Ph.D.  
Investigator  
The Feinstein Institute for Medical Research at Northwell Health



Thank you for your support of pediatric brain tumor research, the Symons lab.

DEDICATED EXPERIENCED SUPPORT

---

# SHARE

---

for women facing breast and ovarian cancers

July 19, 2018

Dear Swim Across America Friends:

On behalf of SHARE and the thousands of women we serve each year, thank you so much for your support of our work on Long Island. Your generosity has enabled us to offer support, outreach, and education programs to medically underserved Latinas, and we are deeply grateful for the opportunity.

In September, 2017 SHARE began a new Spanish-language breast and ovarian cancer support group in Brentwood, Long Island. The group is being held at St. Luke's church, which primarily serves the local immigrant, Latino community. Maria Theresa Romero, a veteran SHARE Ambassador, is facilitating the group. She is being mentored and supported by LatinaSHARE Co-Director Maria Estrella, who has more than a decade of experience facilitating support groups, conducting patient navigation, and heading SHARE's outreach efforts.

The group has been well attended, and SHARE is continuing to engage in intensive promotion to attract new participants. The church promotes the group to its members, and additional promotion takes place through SHARE's partnerships with community groups including Make the Road, and the local El Salvadoran consulate.

In addition to the support group, SHARE has begun providing regular outreach and educational outreach presentations in the community through our Ambassador program. The Ambassador program is a grassroots community organizing effort designed to reach out to African-American, Latina and immigrant women in medically underserved communities. The purpose of these efforts is to reduce outcome disparities in patients with breast or ovarian cancers through bi-lingual education and support initiatives. On Long Island, the outreach presentations have occurred regularly through a partnership with the local El Salvadoran consulate in Brentwood, as well as other locations including Good Samaritan Hospital Medical Center in West Islip, Mercy Medical Center in Rockville Centre, and the Brentwood Library.

We are very pleased to bring the program to Long Island, in order to broaden its reach. One of the most effective components of the Ambassador program has been outreach through 12 consulates in New York City. By replicating this work outside the five boroughs, we are able to reach women and families in some of Long Island's most vulnerable communities with trusted information and resources.

Once again, many thanks for Swim Across America's generous support and partnership. We are so pleased to have the opportunity to work with you, and bring critical support, outreach, and education services to women and families facing a cancer diagnosis on Long Island.

Sincerely,




Jacqueline Reinhard  
Executive Director




## 2017 SOUND TO COVE
















# 2017 NASSAU SUFFOLK POOL SWIMS









proudly supports



Aboff's Paints and Wallcoverings

*proudly supports*

SWIM ACROSS AMERICA'S  
FIGHT AGAINST CANCER

**ABOFF'S**  
The Painter's Choice

33 Long Island Locations | Visit [www.aboffs.com](http://www.aboffs.com)



Since 1989, MIAC® has been the leading provider of pricing, risk management, and accounting solutions for the mortgage and financial services industries

**Proudly supporting  
Swim Across America  
Nassau-Suffolk as they  
make waves to  
defeat cancer**



# Proud Supporter

Morgan Stanley is proud to support  
Swim Across America.

**John F. Coyle III CIMA®, CRPS®**

Family Wealth Director  
Managing Director - Wealth Management  
Financial Advisor  
855 Franklin Ave.  
Garden City, NY 11530  
+1 516 227-2994  
john.coyle@ms.com  
[www.morganstanleyfa.com/foundersgroup](http://www.morganstanleyfa.com/foundersgroup)

## Morgan Stanley

© 2014 Morgan Stanley Smith Barney LLC. Member SIPC.  
SUPO21 CRC 978742 08/14

CS 7903060 08/14


**Proud Supporter and Corporate Sponsor**  
*Swim Across America Sound to the Cove*

**Congratulations to all 2018 Swimmers!**




**Powering the present, empowering your future**  
The world's most powerful networks utilize solutions from  
CommScope

[www.commscope.com](http://www.commscope.com)



**Saluting the efforts of all the swimmers, volunteers and staff of Swim Across America who are building the path to a cure with every stroke they take**


 **Foschi**  
 **Construction Corp.**

We're Proud To  
Support  
Swim Across America's  
Fight Against  
Cancer.

KEEP UP THE GOOD  
WORK!

**LANCER**  
INSURANCE  
*The Difference is Our Attitude.*

370 WEST PARK AVENUE, LONG BEACH, NY 11561



Proudly supporting Swim Across America  
and their network of doctors and researchers  
on the road to developing  
new cures and treatments



**Hewlett Packard  
Enterprise**




**NAPIER PARK**  
GLOBAL CAPITAL

## Napier Park Cares

Napier Park Global continues to support the Swim Across America Nassau-Suffolk swimmers and volunteers in their efforts to make waves to defeat cancer

Napier Park is a global alternative asset management platform with approximately \$10 billion in assets under management. The 100% employee controlled firm offers a broad range of investment products to select institutional investors.

# SOUND TO COVE MORGAN PARK, GLEN COVE, NY 2018 SWIM COURSES



## **10K COURSE:**

For 2018, the 10K swim will start in Larchmont, NY and go across Long Island Sound to the Beach in Glen Cove

## **5K COURSE:**

Starts on beach follows 1 mile course to 2<sup>nd</sup> base (#3), then heads straight out to right field to RED turn around buoy, then follow straight into beach (Follow buoys #1, 2, 3, 5, RED, #6, 4, 1 on your left as noted above)

## **1 MILE COURSE:**

Starts on beach follows baseball diamond shape course back to beach (Follow Buoys #1/2/3/4)

## **1/2 MILE COURSE:**

Follow 1 mile course to 1<sup>st</sup> base, turn around base and return back down 1<sup>st</sup> base line to home plate and beach (Follow buoys #1, 2, back to #1 and to Beach as noted above)



**"I've seen and met  
angels wearing the disguise  
of ordinary people  
living ordinary lives."** - Tracy Chapman

EDF TRADING IS A PROUD SPONSOR OF SWIM ACROSS  
AMERICA IN ITS FIGHT AGAINST CANCER.

